August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS33
Academic Journal
Presents an abstract of the research manuscript `Response-adapted treatment of de novo acute myeloblastic leukemia (AML): Update of a phase II multi-center study of sequential induction regimens idarubicin/cytarabine and mitoxantrone/etoposide,' by R. van der Jagt, S. Robinson et al from the Canadian Leukemia Study Group.


Related Articles

  • CML Blast Crisis: Imatinib Plus Chemotherapy Effective for Some. Ershler, William B. // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p37 

    TREATMENT OF BLAST CRISIS REMAINS A MAJOR challenge. In the current report, Fruehauf and colleagues describe their experience in a phase I/II trial in which patients were treated with imatinib, mitoxantrone, and etoposide using four different treatment schedules. In each schedule, the...

  • Cytarabine/etoposide/mitoxantrone.  // Reactions Weekly;2/21/2004, Issue 989, p8 

    Discusses research being done on a woman with acute myelomonocytic leukaemia who developed recall dermatitis at the site of a scald wound during her treatment with cytarabine, etoposide and mitoxantrone. Reference to a study by C. Y. Chu et al, published in the August 2003 issue of "Acta...

  • Daunorubicin/mitoxantrone.  // Reactions Weekly;6/30/2007, Issue 1158, p12 

    The article describes the case of a boy who developed cardiotoxicity during treatment with daunorubicin and mitoxantrone for acute myeloid leukemia (AML). It references a study by J. S. Rao Mangat et al., published in the June 2007 issue of the "Journal of Heart and Lung Transplantation." The...

  • Fluconazole/mitoxantrone.  // Reactions Weekly;4/7/2007, Issue 1146/1147, p17 

    The article presents the case of a 61-year-old woman who developed torsade de pointes during treatment with mitoxantrone for acute myeloid leukaemia and fluconazole for candidaemia. She was treated with fluconazole 200 milligrams per day and mitoxantrone before admission. Through an...

  • Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study. Kaliks, Rafael; Guerra, Camila; Del Giglio, Auro // Einstein (16794508);Jul2010, Vol. 8 Issue 3, p336 

    Objective: To evaluate the efficacy and toxicity of the association of mitoxantrone and oral etoposide. Methods: Twelve consecutive patients with metastatic hormone-refractory prostate cancer were treated with mitoxantrone and oral etoposide. Toxicity, response rate and response duration were...

  • Cytarabine/mitoxantrone.  // Reactions Weekly;9/20/2008, Issue 1220, p10 

    The article describes the case of a 17-year-old girl who developed Rhodococcus equi bacteraemia and Gordonia polyisoprenivorans while receiving cytarabine and mitoxantrone for undifferentiated myeloblastic leukaemia. The patient developed fever, rhinorrhoea and a productive cough a month after...

  • Mitoxantrone helps decrease pain of PCa.  // Urology Times;Oct96, Vol. 24 Issue 10, p40 

    Reports that the US Food and Drug Administration has recommended for approval mitoxantrone from Immunex for use in hormone-resistant prostate cancer.

  • Dose-dependent melanonychia by mitoxantrone. Reinsberger, C.; Meuth, S. G.; Wiendl, H. // Multiple Sclerosis (13524585);Sep2009, Vol. 15 Issue 9, p1131 

    We report an unusual case of a 43-year old female patient suffering from multiple sclerosis, who was treated with mitoxantrone. Few weeks after treatment initiation a hyperpigmentation of the patient's left thumb and index was noted. Following dose-reduction (from 12 to 10 mg/m²) and over the...

  • Therapy-related leukemia in mitozantrone treated patients. Goodkin, Donald E // Multiple Sclerosis (13524585);Aug2003, Vol. 9 Issue 4, p426 

    Presents case reports of therapy-related leukemia in European patients with multiple sclerosis who have received mitoxantrone as disease modifying therapy. Information on the patients; Risk of using mitoxantrone for multiple sclerosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics